GPR119 is expressed predominantly in the pancreas and intestine of humans and rodents and in rat brain Upon activation of the receptor promotes secretion of a certain hormone called glucagon pharmacy news .-Like Peptide – 1 , in the intestine, which has in turn the insulin secretion from the pancreas, both are key components in the regulation of the equilibrium of glucose in the body. Although some modulators of GPR119 have discovered be used therapeutically. Necessarily mimic the receptor natural ligands and thus have themselves off as mostly unsuitable for use in the investigation of receptor biology and function. ‘With respect to the treatment of metabolic diseases through modulation of GPCRs, ‘McDonald said, ‘an obvious candidate as the GLP – 1 receptor is pursuing a historically difficult target with small molecules, but GPR119 is much more accessible modulation, it also regulates the it also regulates the GLP – 1 axis, which is what makes it such a potentially valuable target for diabetes and obesity, we have this particular receptor for those reasons. , and the fact that it is largely studied by the pharmaceutical industry ‘.
McDonald hopes when the new assays are developed and created molecular probes, wherein the method is for the identification of small molecule compounds that may lead be used therapeutically. The probes themselves might even potential in this regard. – ‘We will study of these study of these probes, the remaining drug-like properties, especially if they have no significant activity against the GPR119 receptor show, ‘she said. ‘would be the obvious target, a probe to improve the therapeutic qualities – oral bioavailability, for example. While maintaining its high activity, a process that is much more difficult than sounds like sounds ‘.
Bladder carcinoma is to fourth most common cancer men in the United States. About 50,000 people be annually each year. Despite early phase surface tumors may be shaved off or treated with BCG immunotherapy, patient with late stages tumor-infiltrating often requires radical cystectomy . Thus , early diagnosis for bladder cancer at critical maintaining lifestyle standards. Non-invasive diagnosis specifically multiplexing ligation dependent probe amplication can be used to screen more target sequences of of a single reaction a single reaction such that for a fast early detection of tumor markers. Are commercially obtainable, however, MS – MLPA kit of many diseases do not available, and customized tube design issues chemical synthesis more nucleotides limited. Researchers working Dr. Per Guldberg the Danish Cancer Society now changed this testing test using multiple short synthetic sensors of tumor markers bladder cancer. They found paired cancer and urine , in most cases showed identical labeling patterns which indicates that this assay non-invasive diagnosis and surveillance of illnesses can be used. Serizawa et al suggests that ‘use of multiple short synthetic probes can an easy and inexpensive solution to offers customized Designs MLPA. ‘In future research will study Dr. Guldberg the group 12: ‘taking the same approach for most other MLPA applications work and therefore the basis the widespread use the MLPA technology. ‘.